EphA2-dependent molecular targeting therapy for malignant tumors

Current Cancer Drug Targets

Volumn 11, Issue 9, 2011, Pages 1082-1097

  Biao Xue, Rong ^a   Xi Guang, Cai ^b   Shuan Ying, Yang ^a   Wei, Li ^a   Zong Juan, Ming ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Anticancer therapy; Cancer; Drug target; EphA2; Neoplasms; Tyrosine kinase inhibitor

Indexed keywords

EPHRIN RECEPTOR A2; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE TARGETING; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPHA2; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 81155126187     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911798073050     Document Type: Review

References (132)

1. Easty, D. J.; Herlyn, M.; Bennett, D. C. Abnormal protein-tyrosine kinase gene-expression during melanoma progression and metastasis. Int. J. Cancer 1995, 60,129-136.
2. Nemoto, T.; Ohashi, K.; Akashi, T.; Johnson, J. D.; Hirokawa, K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997, 65,195-203.
3. Rosenberg, I. M.; Goke, M.; Kanai, M.; Reinecker, H. C.; Podolsky, S. K. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am. J. Physiol. 1997, 273, G824-G832.
4. Zelinski, D. P.; Zantek, N. D.; Stewart, J. C.; Irizarry, A. R.; Kinch, M. S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001, 61, 2301-2306.
5. Walker-Daniels, J.; Coffman, K.; Azimi, M.; Rhim, J. S.; Bostwick, D. G.; Snyder, P.; Kerns, B. J.; Waters, D. J.; Kinch, M. S. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41, 275-280.
6. Bruckheimer, E. M.; Fazenbaker, C. A.; Gallagher, S.; Mulgrew, K.; Fuhrmann, S.; Coffman, K. T.; Walsh, W.; Ready, S.; Cook, K.; Damschroder, M.; Kinch, M.; Kiener, P. A.; Woods, R.; Gao, C.; Dall'Acqua, W.; Wu, H.; Coats, S. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 2009, 11, 509-517.
7. Flanagan, J. G.; Gale, N. W.; Hunter, T.; Pasquale, E. B.; TessierLavigne, M. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 1997, 90, 403-404.
8. Fang, W. B.; Brantley-Sieders, D. M.; Parker, M. A.; Reith, A. D.; Chen, J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005, 24, 7859-7868.
9. Nakamura, R.; Kataoka, H.; Sato, N.; Kanamori, M.; Ihara, M.; Igarashi, H.; Ravshanov, S.; Wang, Y. J.; Li, Z. Y.; Shimamura, T.; Kobayashi, T.; Konno, H.; Shinmura, K.; Tanaka, M.; Sugimura, H. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005, 96, 42-47.
10. Cui, X. D.; Lee, M. J.; Yu, G. R.; Kim, I. H.; Yu, H. C.; Song, E. Y.; Kim, D. G. EFNA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma. Int. J. Cancer 2010, 126, 940-949.
11. Liu, Y.; Zhang, X.; Qiu, Y.; Huang, D.; Zhang, S.; Xie, L.; Qi, L.; Yu, C.; Zhou, X.; Hu, G. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J. Cancer Res. Clin. Oncol. 2011, 137, 761-769.
12. Holder, N.; Klein, R. Eph receptors and ephrins: effectors of morphogenesis. Development 1999, 126, 2033-2044.
13. Dodelet, V. C.; Pasquale, E. B. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000, 19, 5614-5619.
14. Lindberg, R. A.; Hunter, T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol. Cell Biol. 1990, 10, 6316-6324.
15. Davis, S.; Gale, N. W.; Aldrich, T. H.; Maisonpierre, P. C.; Lhotak, V.; Pawson, T.; Goldfarb, M.; Yancopoulos, G. D. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994, 266, 816-819.
16. Beckmann, M. P.; Cerretti, D. P.; Baum, P.; Vandenbos, T.; James, L.; Farrah, T.; Kozlosky, C.; Hollingsworth, T.; Shilling, H.; Maraskovsky, E.; Fletcher, F. A.; Lhotak, V.; Pawson, T.; Lyman, S. D. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J. 1994, 13, 3757-3762.
17. Wykosky, J.; Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 2008, 6, 1795-1806.
18. Bartley, T. D.; Hunt, R. W.; Welcher, A. A.; Boyle, W. J.; Parker, V. P.; Lindberg, R. A.; Lu, H. S.; Colombero, A. M.; Elliott, R. L.; Guthrie, B. A.; Holst, P. L.; Skrine, J. D.; Toso, R. J.; Zhang, M.; Fernandez, E.; Trail, G.; Varnum, B.; Yarden, Y.; Hunter, T.; Fox, G. M. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 1994, 368, 558-560.
19. Himanen, J. P.; Yermekbayeva, L.; Janes, P. W.; Walker, J. R.; Xu, K.; Atapattu, L.; Rajashankar, K. R.; Mensinga, A.; Lackmann, M.; Nikolov, D. B. Architecture of Eph receptor clusters. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 10860-10865.
20. Erzinger, S. A.; Liu, H.; Kiriakova, G.; Price, J. E. EphA2 overexpression in ER-negative metastatic breast cancer cells. Clin. Exp. Metastas. 2011, 28, 219-219.
21. Ogawa, K.; Pasqualini, R.; Lindberg, R. A.; Kain, R.; Freeman, A. L.; Pasquale, E. B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19, 6043-6052.
22. Hess, A. R.; Seftor, E. A.; Gardner, L. M. G.; Carles-Kinch, K.; Schneider, G. B.; Seftor, R. E. B.; Kinch, M. S.; Hendrix, M. J. C. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001, 61, 3250-3255.
23. Cheng, N.; Brantley, D. M.; Liu, H.; Lin, O.; Enriquez, M.; Gale, N.; Yancopoulos, G.; Cerretti, D. P.; Daniel, T. O.; Chen, J. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 2002, 1, 2-11.
24. Kinch, M. S.; Moore, M. B.; Harpole, D. H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 2003, 9, 613-618.
25. Brannan, J. M.; Sen, B.; Saigal, B.; Prudkin, L.; Behrens, C.; Solis, L.; Dong, W. L.; Bekele, B. N.; Wistuba, I.; Johnson, F. M. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev. Res. 2009, 2, 1039-1049.
26. Brannan, J. M.; Dong, W. L.; Prudkin, L.; Behrens, C.; Lotan, R.; Bekele, B. N.; Wistuba, I.; Johnson, F. M. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin. Cancer Res. 2009, 15, 4423-4430.
27. Faoro, L.; Singleton, P. A.; Cervantes, G. M.; Lennon, F. E.; Choong, N. W.; Kanteti, R.; Ferguson, B. D.; Husain, A. N.; Tretiakova, M. S.; Ramnath, N. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J. Biol. Chem. 2010, 285, 18575-18585.
28. Macrae, M.; Neve, R. M.; Rodriguez-Viciana, P.; Haqq, C.; Yeh, J.; Chen, C. R.; Gray, J. W.; McCormick, F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005, 8, 111-118.
29. Fox, B. P.; Kandpal, R. P. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem. Biophys. Res. Commun. 2004, 318, 882-892.
30. Brantley-Sieders, D. M.; Zhuang, G.; Hicks, D.; Bin Fang, W.; Hwang, Y.; Cates, J. M. M.; Coffman, K.; Jackson, D.; Bruckheirner, E.; Muraoka-Cook, R. S.; Chen, J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 2008, 118, 64-78.
31. Pan, M. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status. J. Clin. Oncol. 2005, 23, 857S-857S.
32. Lu, M.; Miller, K. A.; Gokmen-Polar, Y.; Jeng, M. H.; Kinch, M. S. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 2003, 63, 3425-3429.
33. Yang, P.; Yuan, W.; He, J.; Wang, J.; Yu, L.; Jin, X.; Hu, Y.; Liao, M.; Chen, Z.; Zhang, Y. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol. Res. 2009, 39, 1169-1177.
34. Yuan, W. J.; Chen, Z. K.; Wu, S. B.; Ge, J.; Chang, S.; Wang, X. W.; Chen, J. X.; Chen, Z. H. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol. Oncol. Res. 2009, 15, 473-478.
35. Xu, F.; Zhong, W.; Li, J. C.; Zhang, S. S.; Cui, J. C.; Nesland, J. M.; Suo, Z. H. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res. 2005, 25, 2943-2950.
36. Miyazaki, T.; Kato, H.; Fukuchi, M.; Nakajima, M.; Kuwano, H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int. J. Cancer 2003, 103, 657-663.
37. Zeng, G. Y.; Hu, Z. Q.; Kinch, M. S.; Pan, C. X.; Flockhart, D. A.; Kao, C. H.; Gardner, T. A.; Zhang, S. B.; Li, L.; Baldridge, L. A.; Koch, M. O.; Ulbright, T. M.; Eble, J. N.; Cheng, L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am. J. Pathol. 2003, 163, 2271-2276.
38. Lin, Y. G.; Han, L. Y.; Kamat, A. A.; Merritt, W. M.; Landen, C. N.; Deavers, M. I.; Fletcher, M. S.; Urbauer, D. L.; Kinch, M. S.; Sood, A. K. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007, 109, 332-340.
39. Thaker, P. H.; Deavers, M.; Celestino, J.; Thornton, A.; Fletcher, M. S.; Landen, C. N.; Kinch, M. S.; Kiener, P. A.; Sood, A. K. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 2004, 10, 5145-5150.
40. Mudali, S. V.; Fu, B. J.; Lakkur, S. S.; Luo, M. D.; Embuscado, E. E.; Iacobuzio-Donahue, C. A. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin. Exp. Metastasis 2006, 23, 357-365.
41. Duxbury, M. S.; Ito, H.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004, 23, 1448-1456.
42. Abraham, S.; Knapp, D. W.; Cheng, L.; Snyder, P. W.; Mittal, S. K.; Bangari, D. S.; Kinch, M.; Wu, L.; Dhariwal, J.; Mohammed, S. I. Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder. Clin. Cancer Res. 2006, 12, 353-360.
43. Wu, D.; Suo, Z. H.; Kristensen, G. B.; Li, S. S.; Troen, G.; Holm, R.; Nesland, J. M. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol. Oncol. 2004, 94, 312-319.
44. Holm, R.; de Putte, G. V.; Suo, Z.; Lie, A. K.; Kristensen, G. B. Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int. J. Med. Sci. 2008, 5, 121-6.
45. Kataoka, H.; Igarashi, H.; Kanamori, M.; Ihara, M.; Wang, J. D.; Wang, Y. J.; Li, Z. Y.; Shimamura, T.; Kobayashi, T.; Maruyarna, K.; Nakamura, T.; Arai, H.; Kajimura, M.; Hanai, H.; Tanaka, M.; Sugimura, H. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004, 95, 136-141.
46. Saito, T.; Masuda, N.; Miyazaki, T.; Kanoh, K.; Suzuki, H.; Shimura, T.; Asao, T.; Kuwano, H. Expression of EphA2 and E- cadherin in colorectal cancer: Correlation with cancer metastasis. Oncol. Rep. 2004, 11, 605-611.
47. Herrem, C. J.; Tatsumi, T.; Olson, K. S.; Shirai, K.; Finke, J. H.; Bukowski, R. M.; Zhou, M.; Richmond, A. L.; Derweesh, I.; Kinch, M. S.; Storkus, W. J. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin. Cancer Res. 2005, 11, 226-231.
48. Xu, J.S.; Zhang, J.X.; Geng, T.H.; Wang, Y.F.; Wang, X.L.; Zuo, L.F. Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis. Zhonghua Zhongliu Zazhi 2009, 31, 438-441.
49. Wykosky, J.; Gibo, D. M.; Stanton, C.; Debinski, W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 2005, 3, 541-551.
50. Wang, L. F.; Fokas, E.; Bieker, M.; Rose, F.; Rexin, P.; Zhu, Y.; Pagenstecher, A.; Engenhart-Cabillic, R.; An, H. X. Increased expression. of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol. Rep. 2008, 19, 151-156.
51. Liu, F. H.; Park, P. J.; Lai, W.; Maher, E.; Chakravarti, A.; Durso, L.; Jiang, X. L.; Yu, Y.; Brosius, A.; Thomas, M.; Chin, L.; Brennan, C.; DePinho, R. A.; Kohane, I.; Carroll, R. S.; Blacks, P. M.; Johnson, M. D. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 2006, 66, 10815-10823.
52. Miao, H.; Burnett, E.; Kinch, M.; Simon, E.; Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2000, 2, 62-69.
53. Carter, N.; Nakamoto, T.; Hirai, H.; Hunter, T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130 (cas). Nat. Cell Biol. 2002, 4, 565-573.
54. Hess, A. R.; Hendrix, M. J. C. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 2006, 5, 478-480.
55. Liu, D. P.; Wang, Y.; Koeffler, H. P.; Xie, D. Ephrin-A1 is a negative regulator in glioma through down-reguation of EphA2 and FAK. Int. J. Oncol. 2007, 30, 865-871.
56. Wong, K. K. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat. Anticancer Drug Discov. 2009, 4, 28-35.
57. Pratt, R. L.; Kinch, M. S. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002, 21, 7690-7699.
58. Miao, H.; Wei, B. R.; Peehl, D. M.; Li, Q.; Alexandrou, T.; Schelling, J. R.; Rhim, J. S.; Sedor, J. R.; Burnett, E.; Wang, B. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell. Biol. 2001, 3, 527-530.
59. Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 2010, 10, 165-180.
60. Pratt, R. L.; Kinch, M. S. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Mol. Cancer Res. 2003, 1, 1070-1076.
61. Andres, A. C.; Reid, H. H.; Zurcher, G.; Blaschke, R. J.; Albrecht, D.; Ziemiecki, A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 1994, 9, 1461-1467.
62. Menges, C. W.; McCance, D. J. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA(2) receptor. Oncogene 2008, 27, 2934-2940.
63. Dohn, M.; Jiang, J. Y.; Chen, X. B. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 2001, 20, 6503-6515.
64. Zhang, G. Q.; Njaw, C. N.; Park, J. M.; Naruse, C.; Asano, M.; Tsao, H. S. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res. 2008, 68, 1691-1696.
65. Miao, H.; Li, D. Q.; Mukherjee, A.; Guo, H.; Petty, A.; Cutter, J.; Basilion, J. P.; Sedor, J.; Wu, J.; Danielpour, D.; Sloan, A. E.; Cohen, M. L.; Wang, B. C. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009, 16, 9-20.
66. Walker-Daniels, J.; Hess, A. R.; Hendrix, M. J. C.; Kinch, M. S. Differential regulation of EphA2 in normal and malignant cells. Am. J. Pathol. 2003, 162, 1037-1042.
67. Parri, M.; Buricchi, F.; Taddei, M. L.; Giannoni, E.; Raugei, G.; Ramponi, G.; Chiarugi, P. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J. Biol. Chem. 2005, 280, 34008-34018.
68. Kikawa, K. D.; Vidale, D. R.; Van Etten, R. L.; Kinch, M. S. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J. Biol. Chem. 2002, 277, 39274-39279.
69. Fujii, H.; Fujiwara, H.; Horie, A.; Suginami, K.; Sato, Y.; Konishi, I. EphrinA1 stimulates cell attachment and inhibits cell aggregation through the EphA receptor pathway in human endometrial carcinoma-derived Ishikawa cells. Hum. Reprod. 2011, 26, 1163-1170.
70. Orsulic, S.; Kemler, R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. Journal of Cell Sci. 2000, 113, 1793-1802.
71. Zantek, N. D.; Azimi, M.; Fedor-Chaiken, M.; Wang, B. C.; Brackenbury, R.; Kinch, M. S. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 1999, 10, 629-638.
72. Miura, K.; Nam, J. M.; Kojima, C.; Mochizuki, N.; Sabe, H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. Mol. Biol. Cell. 2009, 20, 1949-1959.
73. Carles-Kinch, K.; Kilpatrick, K. E.; Stewart, J. C.; Kinch, M. S. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002, 62, 2840-2847.
74. Fang, W. B.; Brantley-Sieders, D. M.; Hwang, Y.; Ham, A.-J. L.; Chen, J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem. 2008, 283, 16017-26.
75. Zhang, Y. Y.; Thant, A. A.; Hiraiwa, Y.; Naito, Y.; Sein, T. T.; Sohara, Y.; Matsuda, S.; Hamaguchi, M. A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QG90. Biochem. Biophys. Res. Commun. 2002, 290, 1123-1127.
76. Yang, N. Y.; Fernandez, C.; Richter, M.; Xiao, Z.; Valencia, F.; Tice, D. A.; Pasquale, E. B. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal. 2011, 23, 201-212.
77. Hiramoto-Yamaki, N.; Takeuchi, S.; Ueda, S.; Harada, K.; Fujimoto, S.; Negishi, M.; Katoh, H. Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. J. Cell Biol. 2010, 190, 461-477.
78. Gopal, U.; Bohonowych, J. E.; Lema-Tome, C.; Liu, A.; Garrett-Mayer, E.; Wang, B. C.; Isaacs, J. S. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. Plos One 2011, 6, e17649.
79. Wu, N.; Zhao, X. Z.; Liu, M.; Liu, H. Z.; Yao, W. C.; Zhang, Y. Y.; Cao, S. S.; Lin, X. K. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. Plos One 2011, 6, e16264.
80. Brantley-Sieders, D. M.; Dunaway, C. M.; Rao, M.; Short, S.; Hwang, Y.; Gao, Y. D.; Li, D. Y.; Jiang, A. X.; Shyr, Y.; Wu, J. Y.; Chen, J. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res. 2011, 71, 976-987.
81. Shekhar, M. P. V.; Werdell, J.; Santner, S. J.; Pauley, R. J.; Tait, L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: Implications for tumor development and progression. Cancer Res. 2001, 61, 1320-1326.
82. Merritt, W. M.; Kamat, A. A.; Hwang, J. Y.; Bottsford-Miller, J.; Lu, C.; Lin, Y. G.; Coffey, D.; Spannuth, W.; Nugent, E.; Han, L. Y. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol. Ther. 2010, 10, 1306-1314.
83. Pandey, A.; Shao, H. N.; Marks, R. M.; Polverini, P. J.; Dixit, V. M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 1995, 268, 567-569.
84. Larson, J.; Schomberg, S.; Schroeder, W.; Carpenter, T. C. Endothelial EphA receptor stimulation increases lung vascular permeability. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L431-L439.
85. Brantley-Sieders, D. M.; Caughron, J.; Hicks, D.; Pozzi, A.; Ruiz, J. C.; Chen, J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell Sci. 2004, 117, 2037-2049.
86. Brantley-Sieders, D. M.; Fang, W. B.; Hicks, D. J.; Zhuang, G.; Yu, S.; Chen, J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J. 2005, 19, 1884-1886.
87. Baharvand, H.; Ashtiani, S. K.; Taee, A.; Massumi, M.; Valojerdi, M. R.; Yazdi, P. E.; Moradi, S. Z.; Farrokhi, A. Generation of new human embryonic stem cell lines with diploid and triploid karyotypes. Dev. Growth Differ. 2006, 48, 117-128.
88. Lickliter, J. D.; Smith, F. M.; Olsson, J. E.; Mackwell, K. L.; Boyd, A. W. Embryonic stem cells express multiple Eph-subfamily receptor tyrosine kinases. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 145-150.
89. Lazarova, P.; Wu, Q.; Kvalheim, G.; Suo, Z.; Haakenstad, K. W.; Metodiev, K.; Nesland, J. M. Growth factor receptors in hematopoietic stem cells: Eph family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood. Int. J. Immunopathol. Pharmacol. 2006, 19, 49-56.
90. Goichberg, P.; Bai, Y.; D'Amario, D.; Ferreira-Martins, J.; Fiorini, C.; Zheng, H.; Signore, S.; del Monte, F.; Ottolenghi, S.; D'Alessandro, D. A. The ephrin A1-EphA2 system promotes cardiac stem cell migration after infarction. Circ. Res. 2011, 108, 1071-1083.
91. Genander, M.; Frisén, J. Ephrins and Eph receptors in stem cells and cancer. Curr. Opin. Cell Biol. 2010, 22, 611-616.
92. Tumbar, T.; Guasch, G.; Greco, V.; Blanpain, C.; Lowry, W. E.; Rendl, M.; Fuchs, E. Defining the epithelial stem cell niche in skin. Science 2004, 303, 359-363.
93. Guo, H.; Miao, H.; Gerber, L.; Singh, J.; Denning, M. F.; Gilliam, A. C.; Wang, B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res. 2006, 66, 7050-7058.
94. Ireton, R. C.; Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets 2005, 5, 149-157.
95. Kumar, S. R.; Masood, R.; Spannuth, W. A.; Singh, J.; Scehnet, J.; Kleiber, G.; Jennings, N.; Deavers, M.; Krasnoperov, V.; Dubeau, L.; Weaver, F. A.; Sood, A. K.; Gill, P. S. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br. J. Cancer 2007, 96, 1083-1091.
96. Kumar, S. R.; Scehnet, J. S.; Ley, E. J.; Singh, J.; Krasnoperov, V.; Liu, R.; Manchanda, P. K.; Ladner, R. D.; Hawes, D.; Weaver, F. A.; Beart, R. W.; Singh, G.; Nguyen, C.; Kahn, M.; Gill, P. S. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009, 69, 3736-3745.
97. Landen, C. N.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M. T.; Lopez-Berestein, G.; Sood, A. K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65, 6910-6918.
98. Kuijper, S.; Turner, C. J.; Adams, R. H. Regulation of angiogenesis by Eph-Ephrin interactions. Trends Cardiovasc. Med. 2007, 17, 145-151.
99. Scehnet, J. S.; Ley, E. J.; Krasnoperov, V.; Liu, R.; Manchanda, P. K.; Sjoberg, E.; Kostecke, A. P.; Gupta, S.; Kumar, S. R.; Gill, P. S. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 2009, 113, 254-263.
100. Zhou, Z.; Yuan, X.; Li, Z.; Tu, H.; Li, D.; Qing, J.; Wang, H.; Zhang, L. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg. Neurol. 2008, 70, 562-568.
101. Nasreen, N.; Mohammed, K. A.; Antony, V. B. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006, 107, 2425-2435.
102. Kinch, M. S.; Kiener, P. A.; Bruckheimer, E.; Dubensky, T. W.; Cook, D. N. Listeria-based EphA2 vaccines. U.S. Patent 0281783A1, DEC 22, 2005.
103. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
104. Chang, Q.; Jorgensen, C.; Pawson, T.; Hedley, D. W. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br. J. Cancer 2008, 99, 1074-1082.
105. Larsen, A. B.; Pedersen, M. W.; Stockhausen, M. T.; Grandal, M. V.; van Deurs, B.; Poulsen, H. S. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol. Cancer Res. 2007, 5, 283-293.
106. Lee, J. W.; Han, H. D.; Shahzad, M. M. K.; Kim, S. W.; Mangala, L. S.; Nick, A. M.; Lu, C.; Langley, R. R.; Schmandt, R.; Kim, H. S. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 2009, 101, 1193-1205.
107. Lee, J. W.; Stone, R. L.; Lee, S. J.; Nam, E. J.; Roh, J. W.; Nick, A. M.; Han, H. D.; Shahzad, M. M. K.; Kim, H. S.; Mangala, L. S. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin. Cancer Res. 2010, 16, 2562-2570.
108. Cai, W.; Ebrahimnejad, A.; Chen, K.; Cao, Q.; Li, Z. B.; Tice, D. A.; Chen, X. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 2024-2036.
109. Wesa, A. K.; Herrem, C. J.; Mandic, M.; Taylor, J. L.; Vasquez, C.; Kawabe, M.; Tatsumi, T.; Leibowitz, M. S.; Finke, J. H.; Bukowski, R. M.; Bruckheimer, E.; Kinch, M. S.; Storkus, W. J. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J. Immunol. 2008, 181, 7721-7727.
110. Kiewlich, D.; Zhang, J. H.; Gross, C.; Xia, W.; Larsen, B.; Cobb, R. R.; Biroc, S.; Gu, J. M.; Sato, T.; Light, D. R.; Heitner, T.; Willuda, J.; Vogel, D.; Monteclaro, F.; Citkowicz, A.; Roffler, S. R.; Zajchowski, D. A. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 2006, 8, 18-30.
111. Coffman, K. T.; Hu, M.; Carles-Kinch, K.; Tice, D.; Donacki, N.; Munyon, K.; Kifle, G.; Woods, R.; Langermann, S.; Kiener, P. A.; Kinch, M. S. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 2003, 63, 7907-7912.
112. Kmen-Polar, Y. G.; Toroni, R. A.; Hocevar, B. A.; Badve, S.; Zhao, Q.; Shen, C.; Bruckheimer, E.; Kinch, M. S.; Miller, K. D. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res. Treat. 2010, 127, 1-10.
113. Hammond, S. A.; Lutterbuese, R.; Roff, S.; Lutterbuese, P.; Schlereth, B.; Bruckheimer, E.; Kinch, N. S.; Coats, S.; Baeuerle, P. A.; Kufer, P.; Kiener, P. A. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 2007, 67, 3927-3935.
114. Hatano, M.; Kuwashima, N.; Tatsumi, T.; Dusak, J. E.; Nishimura, F.; Reilly, K. M.; Storkus, W. J.; Okada, H. Vaccination with EphA 2-derived T cell-epitopes promotes immunity against both EphA 2-expressing and EphA 2-negative tumors. J. Transl. Med. 2004, 2, 40.
115. Zhang, J. G.; Eguchi, J.; Kruse, C. A.; Gomez, G. G.; Fakhrai, H.; Schroter, S.; Ma, W.; Hoa, N.; Minev, B.; Delgado, C. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res. 2007, 13, 566-575.
116. Tatsumi, T.; Herrem, C. J.; Olson, W. C.; Finke, J. H.; Bukowski, R. M.; Kinch, M. S.; Ranieri, E.; Storkus, W. J. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003, 63, 4481-4489.
117. Alves, P.; Faure, O.; Graff-Dubois, S.; Gross, D.; Cornet, S.; Chouaib, S.; Miconnet, I.; Lemonnier, F.; Kosmatopoulos, K. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res. 2003, 63, 8476-8480.
118. Yamaguchi, S.; Tatsumi, T.; Takehara, T.; Sakamori, R.; Uemura, A.; Mizushima, T.; Ohkawa, K.; Storkus, W. J.; Hayashi, N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110, 1469-1477.
119. Hatano, M.; Eguchi, J.; Tatsumi, T.; Kuwashima, N.; Dusak, J. E.; Kinch, M. S.; Pollack, I. F.; Hamilton, R. L.; Storkus, W. J.; Okada, H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (New York, NY) 2005, 7, 717-722.
120. Shahzad, M. M. K.; Lu, C. H.; Lee, J. W.; Stone, R. L.; Mitra, R.; Mangala, L. S.; Lu, Y. L.; Baggerly, K. A.; Danes, C. G.; Nick, A. M.; Halder, J.; Kim, H. S.; Vivas-Mejia, P.; Landen, C. N.; Lopez-Berestein, G.; Coleman, R. L.; Sood, A. K. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol. Ther. 2009, 8, 1027-1034.
121. Dobrzanski, P.; Hunter, K.; Jones-Bolin, S.; Chang, H.; Robinson, C.; Pritchard, S.; Zhao, H.; Ruggeri, B. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004, 64, 910-919.
122. Noberini, R.; Koolpe, M.; Peddibhotla, S.; Dahl, R.; Su, Y.; Cosford, N. D. P.; Roth, G. P.; Pasquale, E. B. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J. Biol. Chem. 2008, 283, 29461-29472.
123. Landen, C. N.; Lu, C.; Han, L. Y.; Coffman, K. T.; Bruckheimer, E.; Halder, J.; Mangala, L. S.; Merritt, W. M.; Lin, Y. G.; Gao, C.; Schmandt, R.; Kamat, A. A.; Li, Y.; Thaker, P.; Gershenson, D. M.; Parikh, N. U.; Gallick, G. E.; Kinch, M. S.; Sood, A. K. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl. Cancer Inst. 2006, 98, 1558-1570.
124. Koolpe, M.; Dail, M.; Pasquale, E. B. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem. 2002, 277, 46974-46979.
125. Jackson, D.; Gooya, J.; Mao, S. L.; Kinneer, K.; Xu, L. D.; Camara, M.; Fazenbaker, C.; Fleming, R.; Swamynathan, S.; Meyer, D.; Senter, P. D.; Gao, C.; Wu, H. R.; Kinch, M.; Coats, S.; Kiener, P. A.; Tice, D. A. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008, 68, 9367-9374.
126. Van Geer, M. A.; Bakker, C. T.; Koizumi, N.; Mizuguchi, H.; Wesseling, J. G.; Elferink, R.; Bosma, P. J. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J. Gastroenterol. 2009, 15, 2754-2762.
127. Scarberry, K. E.; Dickerson, E. B.; McDonald, J. F.; Zhang, Z. J. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc. 2008, 130, 10258-10262.
128. Scarberry, K. E.; Dickerson, E. B.; Zhang, Z. J.; Benigno, B. B.; McDonald, J. F. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine 2010, 6, 399-408.
129. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 2237-2246.
130. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial. JAMA 2003, 290, 2149-2158.
131. Hirsch, F. R.; Varella-Garcia, M.; Bunn, P. A.; Di Maria, M. V.; Veve, R.; Bremnes, R. M.; Baron, A. E.; Zeng, C.; Franklin, W. A. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003, 21, 3798-3807.
132. Suzuki, S.; Dobashi, Y.; Sakurai, H.; Nishikawa, K.; Hanawa, M.; Ooi, A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas - An immunohistomchemical and fluorescence in situ hybridization study. Cancer 2005, 103, 1265-1273.